GHRH raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-23. Anything still debated is marked as such rather than presented as settled.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
== History == Valproic acid was first synthesized in 1882 by Beverly S. Burton as an analogue of valeric acid, found naturally in valerian. Valproic acid is a carboxylic acid, a clear liquid at room temperature. For many decades, its only use was in laboratories as a "metabolically inert" solvent for organic compounds. In 1962, the French researcher Pierre Eymard serendipitously discovered the anticonvulsant properties of valproic acid while using it as a vehicle for a number of other compounds that were being screened for antiseizure activity. He found it prevented pentylenetetrazol-induced convulsions in laboratory rats. It was approved as an antiepileptic drug in 1967 in France and has become the most widely prescribed antiepileptic drug worldwide. Valproic acid has also been used for migraine prophylaxis and bipolar disorder.
=== First Nations relations === In March 2021, Ford publicly accused MPP Sol Mamakwa of "jumping the line" to receive his second dose of a COVID-19 vaccine, despite being eligible to receive it. Mamakwa went to his riding to receive the vaccine as an attempt to prevent vaccine hesitancy amongst his constituents. On Thursday, March 11, 2021, Ford apologised for his remark and later said he "got a little personal" when throwing the accusation at Mamakwa. Mamakwa did not say that he accepted Ford's apology but stated that he appreciated the call from Ford. In September 2021, an Ontario judge issued an injunction on mining in Wiisinin Zaahgi'igan (an area sacred to the Ginoogaming First Nation peoples). The judge ruled that the Ontario government did not consult with the Ginoogaming as is their constitutional duty. Ford's 2024 Reducing Gridlock, Saving you Time Act removed the requirement for future Indigenous consultation for the upcoming Highway 413 in a possible contravention of Ontario's Environmental Assessment Act. In addition, the Indigenous consultation period for the bill was only 30 days, decried by the regional chief as 'too short'. Many Indigenous and environmental advocacy groups opposed his government's Protecting Ontario by Unleashing Our Economy Act, or Bill 5, which gives Ford's cabinet the ability to create special economic zones and exempt companies or projects from having to comply with any provincial law, provincial regulation or municipal bylaw. Ford also apologized for saying that First Nations "keep coming hat in hand" for government money in June 2025.
== Timeline == After filing for bankruptcy, ownership of the hospital went up for bid, and there were two major corporations interested: Adventist Health with University of California San Francisco (UCSF) and American Advanced Management. During this time, a loan of 57 million dollars was approved for the reopening of the hospital from a state funded 300 million dollar bailout program for struggling hospitals in California. Ultimately, the bankruptcy court approved the bid from American Advanced Management in mid February 2024. The hospital has since been moving forward with rebuilding and upgrading, and CEO Steve Stark has goals to reopen by February 2025, given that they are able to fill the necessary positions.
== Medical use == Diphenoxylate is used to treat diarrhea in adults; it is only available as a combination drug with a subtherapeutic dose of atropine to prevent abuse. It should not be used in children due to the risk of respiratory depression. It does not appear harmful to a fetus but the risks have not been fully explored. It should not be taken with other central depressants like alcohol, as they can increase its risks. It should not be used for people with diarrhea caused by an infection, for example with Clostridioides difficile infection, since the slowing of peristalsis can prevent clearing of the infectious organism.
Deupsilocin (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; former developmental code names HLP003 and CYB0003), also known as deuterated psilocin or as psilocin-d10, is a psychedelic drug of the tryptamine family related to psilocin which is under development for the treatment of major depressive disorder, alcoholism, and other psychiatric disorders. It is taken orally. The drug is a deuterated isotopologue of psilocin with altered pharmacokinetics.
Sources: en.wikipedia.org
==== Mechanism of action ==== A photosensitizer generates ROS through one of two processes. Type I involves a redox reaction that results in the creation of superoxides (O2•−), hydroxyl radicals (OH•), and radical peroxides, whereas Type II generates singlet oxygen directly through an electron transfer from the photosensitizer. These ROS go on to nonspecifically damage a variety of cellular components, including proteins, DNA, and lipids as they seek to remove the radical.
==== Yogācāra ==== The yogācāra school interpreted the doctrine of dependent origination through its central schema of the "three natures" (which are really three ways of looking at one dependently originated reality). In this schema, the constructed or fabricated nature is an illusory appearance (of a dualistic self), while the "dependent nature" refers specifically to the process of dependent origination or as Jonathan Gold puts it "the causal story that brings about this seeming self." Furthermore, as Gold notes, in Yogacara, "this causal story is entirely mental," and so our body, sense bases and so on are illusory appearances. Indeed, D.W. Mitchell writes that yogācāra sees consciousness as "the causal force" behind dependent arising. Dependent origination is therefore "the causal series according to which the mental seeds planted by previous deeds ripen into the appearance of the sense bases". This "stream of dependent mental processes" as Harvey describes it, is what generates the subject-object split (and thus the idea of a '"self" and "other" things which are not the self). The third nature then, is the fact that dependent origination is empty of a self, the fact that even though self (as well as an "other", that which is apart from the self) appears, it does not exist.
== Edibility == While sources on the edibility of P.arhizus differ regarding its safety, it’s worth noting that it could be toxic and eating it is not a safe choice. While one paper mentions putting it in soup, it’s not recommended due to its unappealing texture, taste, and consistency. Due to its growth habits it is speculated that the fungi can absorb and contain pollutants or harmful compounds from its environment.
===== Chain of any number of decays ===== For the general case of any number of consecutive decays in a decay chain, i.e. A1 → A2 ··· → Ai ··· → AD, where D is the number of decays and i is a dummy index (i = 1, 2, 3, ..., D), each nuclide population can be found in terms of the previous population. In this case N2 = 0, N3 = 0, ..., ND = 0. Using the above result in a recursive form:
The importance of membrane technology is growing in the field of environmental protection (Nano-Mem-Pro IPPC Database). Even in modern energy recovery techniques, membranes are increasingly used, for example in fuel cells and in osmotic power plants.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.